Abstract
Neoadujuvant chemoradiotherapy combined with total mesorectal excision (TME) is the standard treatment modality for locally advanced rectal cancer (LARC).Targeted drugs in LARC neoadjuvant therapy are well tolerated and safety,but compared with conventional neoadjuvant chemoradiotherapy,the pathologic complete response (pCR) rate is not increased.Large sample randomized controlled trials are needed to confirm the effects of targeted drugs in the neoadjuvant treatment of LARC. Key words: Rectal neoplasms; Receptor, epidermal growth factor; Receptors, vascular endothelial growth factor; Neoadjuvant therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
